ELIDEL CANCERS & PROTOPIC CANCERS, LYMPHOMAS & FDA WARNINGS
The Food and Drug Administration (FDA) has advised health care professionals that Elidel (pimecrolimus) and Protopic (tacrolimus) have failed to work and that because of a potential cancer risk associated with their use that a black box warning is forthcoming. The two eczema creams Elidel and Protopic, must carry a strong warning of cancer risk. The Food and Drug Administration said Thursday.research shows the creams are absorbed into the body and can cause skin cancer and lymphoma. The creams will carry a “black box” warning, which is the strongest warning carried on drugs and medicines.
Talk to a Lawyer at www.Elidel-Cancer.com about a ELIDEL CANCER LAWSUIT
ECZEMA DRUGS POSSIBLY LINKED TO CANCER & LYMPHOMA
The Food and Drug Administration (FDA) has advised health care professionals that Elidel (pimecrolimus) and Protopic (tacrolimus) have failed to work and that because of a potential cancer risk associated with their use that a black box warning is forthcoming. The two eczema creams Elidel and Protopic, must carry a strong warning of cancer risk. The Food and Drug Administration said Thursday.research shows the creams are absorbed into the body and can cause skin cancer and lymphoma. The creams will carry a “black box” warning, which is the strongest warning carried on drugs and medicines. Further the FDA stated that babies should not be treated with the creams at all, the FDA said.“The data showed that the risk of cancer increased as the amount of the drug given increased. The FDA said in a statement the data also included a small number of reports of cancers in children and adults treated with Elidel or Protopic.
ELIDEL & PROTOPIC NOT APPROVED TO TREAT INFANTS
In February 2005, a FDA advisory panel said they were concerned the companies were aggressively advertising the medicines to treat infants and others with skin problems the creams which these creams were not approved to treat.Elidel, known generically as pimecrominum, and Protopic known generically as tacrolimus, should be used only as directed and only after other eczema treatments have failed to work because of the risk, the FDA said.
ELIDEL & PROTOPIC LINKED TO SKIN CANCER & LYMPHOMA
Since the FDA approved Protopic in 2000 and Elidel in 2001, seven cases of lymphoma and six skin cancer cases have been reported in patients, the FDA said.Animal tests have suggested the creams could cause cancer, the FDA added.“The manufacturers of the products have agreed to conduct research to determine whether there is an actual risk of cancer in humans, and, if so, its extent,” the FDA said.“Both products are applied to the skin to control eczema by suppressing the immune system. FDA’s Public Health Advisory specifically advises physicians to weigh the risks and benefits of these drugs in adults and children,” the agency added.
ELIDEL WARNING & PROTOPIC WARNINGS TO USERS
If you or a loved one have used Elidel or Protopic and you have been diagnosed with Cancer, Lymphoma, Tumors or other Immune System Disorders, then call us immediately to discuss what can be done to protect your legal rights. FREE CONFIDENTIAL CONSULTATION at 1-800-883-9858 or 1-800-468-4878 (Toll Free)
The Willis Firm is currently investigating potential legal actions on behalf of a number of Elidel & Protopic users and their families. Additionally Mr. Willis is talking to leading oncologists and immunologists in order to assembly a medical and legal team to investigate and pursue possible products liability claims and lawsuits against the makers and distributors of these two drugs.
Mr. Willis is a Board Certified Personal Injury Trial Lawyer, certified by the Texas Board of Legal Specialization. For a Free Evaluation of your Elidel Lawsuit or Protopic Lawsuit Claim, please complete the following form and we will contact you promptly. This information will not be shared with anyone outside the Willis Law Firm and will remain confidential at all times. Talk with a Board Certified Personal Injury Trial Lawyer about your legal rights of a against the drug industry and others.
Call Us Toll Free at 1-800-883-9858 or 1-800-468-4878 or E-mail us your questions on Free Case Evaluation Form.
Thursday, September 27, 2007
Tuesday, August 14, 2007
Dates on Credit & Debit Card Receipt Law
FACTA Claim / Lawsuit - Dates on Receipt / More Than 5 Digits of Credit Card or Debit Card
The passage of the FACTA, Fair and Accurate Credit Transactions Act in 2003, which amended the Fair Credit Reporting Act (15 USC § 1681 et seq.), required consumer reporting agencies to provide consumers with one free copy of their credit report each year so that errors and corrections could be made and as a protection against the exploding crime of identity theft.
Debit & Credit Card Law Concerning Expiration Date on Credit & Debit Card Receipt
Many lawsuits have been filed regarding merchants printing more than five digits of customers' credit / debit card numbers and/or including the expiration date of the credit card on the receipt. Under FACTA it is a violation to include the expiration date on the credit card receipt or more than Five (5) digits of the
Date on Credit Card Receipt Violations
Talk to a Lawyer / Attorney if have a FACTA Lawsuit or Claim under FACTA if you have a receipt that contains more than Five (5) digits or Five (5) numbers of your debit or credit card or if the credit receipt has the expiration date of your credit or debit card on the receipt. You may have a claim. Call for a Free Confidential Consultation at 1-800-883-9858
Federal Law Concerning Expiration Dates on Debit / Credit Card Receipts
Section 1681c(g) of FACTA prohibits businesses that accept credit or debit cards from including "more than the last Five (5) digits of the card number or the expiration date" on electronically printed receipts provided to the customer at the point of sale or transaction. The lawsuits allege that each electronically printed receipt containing more than the last five digits of a credit or debit card number or a card's expiration date violates Art.1681c(g). The suits specifically allege willful noncompliance (15 U.S.C. Art. 1681n) for the claimed violations and seek statutory damages of $100 (minimum) to $1,000 (maximum) for each violation alleged, plus punitive damages and attorneys's fees. Typically in these cases, the defendant retailer had complied with the first provision of the statute by reducing the number of printed digits to five or less. Most of these target retailers failed, however, to "mask" the card's expiration date. Moreover, and as permitted under a literal reading of the statutory scheme, the plaintiffs in these cases concede they sustained no actual injury or harm.
Damages / Penalties Regarding Merchants Printing Expiration Dates on Debit or Credit Card Receipts
Thus, a noncomplying retailer may be subject to an award of statutory damages ranging from $100 to $1000. Notably, the Fair Credit Reporting Act (FACTA)does not cap the aggregate of statutory damages that can be awarded in a consumer class action.
Date on Debit / Credit Card Receipt Lawsuit - Talk to a Lawyer / Attorney
Talk to a Lawyer / Attorney if have a FACTA Lawsuit or Claim under FACTA if you have a receipt that contains more than Five (5) digits or Five (5) numbers on your debit / credit card or if the debit credit receipt has the expiration date of your credit card on the receipt. Call for a Free Confidential Consultation at 1-800-883-9858
The passage of the FACTA, Fair and Accurate Credit Transactions Act in 2003, which amended the Fair Credit Reporting Act (15 USC § 1681 et seq.), required consumer reporting agencies to provide consumers with one free copy of their credit report each year so that errors and corrections could be made and as a protection against the exploding crime of identity theft.
Debit & Credit Card Law Concerning Expiration Date on Credit & Debit Card Receipt
Many lawsuits have been filed regarding merchants printing more than five digits of customers' credit / debit card numbers and/or including the expiration date of the credit card on the receipt. Under FACTA it is a violation to include the expiration date on the credit card receipt or more than Five (5) digits of the
Date on Credit Card Receipt Violations
Talk to a Lawyer / Attorney if have a FACTA Lawsuit or Claim under FACTA if you have a receipt that contains more than Five (5) digits or Five (5) numbers of your debit or credit card or if the credit receipt has the expiration date of your credit or debit card on the receipt. You may have a claim. Call for a Free Confidential Consultation at 1-800-883-9858
Federal Law Concerning Expiration Dates on Debit / Credit Card Receipts
Section 1681c(g) of FACTA prohibits businesses that accept credit or debit cards from including "more than the last Five (5) digits of the card number or the expiration date" on electronically printed receipts provided to the customer at the point of sale or transaction. The lawsuits allege that each electronically printed receipt containing more than the last five digits of a credit or debit card number or a card's expiration date violates Art.1681c(g). The suits specifically allege willful noncompliance (15 U.S.C. Art. 1681n) for the claimed violations and seek statutory damages of $100 (minimum) to $1,000 (maximum) for each violation alleged, plus punitive damages and attorneys's fees. Typically in these cases, the defendant retailer had complied with the first provision of the statute by reducing the number of printed digits to five or less. Most of these target retailers failed, however, to "mask" the card's expiration date. Moreover, and as permitted under a literal reading of the statutory scheme, the plaintiffs in these cases concede they sustained no actual injury or harm.
Damages / Penalties Regarding Merchants Printing Expiration Dates on Debit or Credit Card Receipts
Thus, a noncomplying retailer may be subject to an award of statutory damages ranging from $100 to $1000. Notably, the Fair Credit Reporting Act (FACTA)does not cap the aggregate of statutory damages that can be awarded in a consumer class action.
Date on Debit / Credit Card Receipt Lawsuit - Talk to a Lawyer / Attorney
Talk to a Lawyer / Attorney if have a FACTA Lawsuit or Claim under FACTA if you have a receipt that contains more than Five (5) digits or Five (5) numbers on your debit / credit card or if the debit credit receipt has the expiration date of your credit card on the receipt. Call for a Free Confidential Consultation at 1-800-883-9858
Thursday, August 2, 2007
ReNu Recall -ReNu with MoistureLoc Contact Solution Class Action Lawsuit
ReNu with MoistureLoc Contact Solution - ReNu Recall
In February 2006, Bausch & Lomb stopped all sales of ReNu in Hong Kong and Singapore because of an increase in eye infection. The American Optometric Association estimates that, "there are over 30 million contact lens wearers in the United States."
In April 2006, ReNu manufacturer Bausch & Lomb suspended sales of its ReNu with MoistureLoc contact lens solution. Bausch & Lomb made this decision after health officials linked ReNu to a serious fungal infection of the eye - Fusarium keratitis. As of April 9, there were 109 cases of suspected Fusarium keratitis under investigation by the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), and health authorities in 17 states. Although only 30 of those patients have been interviewed, 26 of the 28 who wore soft contact lenses reported using ReNu brand products. Eight patients had to undergo corneal transplants. The risk of contracting contact lens-related infection from the Fusarium fungus, which is commonly found in soil, tap water and many plants, is estimated to be 4 to 21 per 100,000 patients.
In May 2006, Bausch & Lomb announced that cases of Fusarium keratitis had been reported by ReNu consumers in Europe, the first time the company acknowledged European cases since the news of the fungus went public. The Centers for Disease Control and Prevention also stated that over a dozen people diagnosed with the fungus had used a different ReNu product, ReNu Multiplus, which the company is still selling. In at least six separate cases, according to the CDC, people used solutions from two other companies.
On May 15th, 2006, Bausch & Lomb announced that they would permanently withdraw ReNu with MoistureLoc. ReNu with MoistureLoc is the contact lens cleaner viewed as the "potential root cause" of the fungal eye infection outbreak known to cause blindness. The Food and Drug Administration has reported that the eye-care company thinks ReNu with MoistureLoc's unique disinfecting and moisturizing agents "in certain unusual circumstances can increase the risk" of developing Fusarium keratitis.
Talk to a Keratitis Lawyer / Attorney - Call 1-800-883-9858
In February 2006, Bausch & Lomb stopped all sales of ReNu in Hong Kong and Singapore because of an increase in eye infection. The American Optometric Association estimates that, "there are over 30 million contact lens wearers in the United States."
In April 2006, ReNu manufacturer Bausch & Lomb suspended sales of its ReNu with MoistureLoc contact lens solution. Bausch & Lomb made this decision after health officials linked ReNu to a serious fungal infection of the eye - Fusarium keratitis. As of April 9, there were 109 cases of suspected Fusarium keratitis under investigation by the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), and health authorities in 17 states. Although only 30 of those patients have been interviewed, 26 of the 28 who wore soft contact lenses reported using ReNu brand products. Eight patients had to undergo corneal transplants. The risk of contracting contact lens-related infection from the Fusarium fungus, which is commonly found in soil, tap water and many plants, is estimated to be 4 to 21 per 100,000 patients.
In May 2006, Bausch & Lomb announced that cases of Fusarium keratitis had been reported by ReNu consumers in Europe, the first time the company acknowledged European cases since the news of the fungus went public. The Centers for Disease Control and Prevention also stated that over a dozen people diagnosed with the fungus had used a different ReNu product, ReNu Multiplus, which the company is still selling. In at least six separate cases, according to the CDC, people used solutions from two other companies.
On May 15th, 2006, Bausch & Lomb announced that they would permanently withdraw ReNu with MoistureLoc. ReNu with MoistureLoc is the contact lens cleaner viewed as the "potential root cause" of the fungal eye infection outbreak known to cause blindness. The Food and Drug Administration has reported that the eye-care company thinks ReNu with MoistureLoc's unique disinfecting and moisturizing agents "in certain unusual circumstances can increase the risk" of developing Fusarium keratitis.
Talk to a Keratitis Lawyer / Attorney - Call 1-800-883-9858
Complete MoisturePlus - Keratitis Eye Infections
FDA MoisturePlus Keratitis Alert
Advanced Medical Optics Recalls Complete MoisturePlus Contact Lens Solution
May 26, 2007
The U.S. Food and Drug Administration is alerting health care professionals and their patients who wear soft contact lenses about a voluntary recall ( see Complete MoisturePlus Recall ) of Complete MoisturePlus Multi Purpose Solution manufactured by Advanced Medical Optics of Santa Ana, Ca.
The company is taking this action as a precaution because of reports of a rare, but serious, eye infection, Acanthamoeba keratitis caused by a parasite. The link between the solution and the infection was identified as a result of an investigation by the Centers for Disease Control and Prevention (CDC).
Consumers who wear soft contact lenses should stop using the solution, discard all partially-used or unopened bottles and replace their lenses and storage container."We believe the company acted responsibly in taking this voluntary action and support their decision to be proactive in the interest of public health," said Daniel Schultz, M.D., director of FDA's Center for Devices and Radiological Health. "FDA and CDC are working closely with the company to collect additional information and we will continue to alert consumers and advise them as more information becomes available."
Acanthamoeba keratitis may lead to vision loss with some patients requiring a corneal transplant. The infection primarily affects otherwise healthy people who wear contact lenses.Consumers should ask their doctor about choosing an appropriate alternative cleaning/disinfecting product and seek immediate treatment if they have symptoms of eye infection as early diagnosis is important for effective treatment. The symptoms of Acanthamoeba keratitis can be very similar to those of other more common eye infections and may include eye pain or redness, blurred vision, light sensitivity, sensation of something in the eye or excessive tearing but Acanthamoeba is more difficult to treat.
It is estimated that Acanthamoeba keratitis infections occur in approximately 2 out of every 1 million contact lens users in the United States each year. However, in a multi-state investigation to evaluate a recent increase in Acanthamoeba keratitis cases, CDC determined that the risk of developing AK was at least seven times greater for those consumers who used Complete MoisturePlus solution versus those who did not. Additional information regarding the CDC results is available at the CDC website http://www.cdc.gov/mmwr/preview/mmwrhtml/mm56d526a1.htm.
"The ongoing CDC investigation is a collaborative effort," said Michael Beach, M.D., a Division of Parasitic Diseases team leader with CDC. "We are working with FDA, state, territory, university, and clinical partners in an effort to further understand whether usage or contamination of this solution led to these Acanthamoeba infections."
Advanced Medical Optics Recalls Complete MoisturePlus Contact Lens Solution
May 26, 2007
The U.S. Food and Drug Administration is alerting health care professionals and their patients who wear soft contact lenses about a voluntary recall ( see Complete MoisturePlus Recall ) of Complete MoisturePlus Multi Purpose Solution manufactured by Advanced Medical Optics of Santa Ana, Ca.
The company is taking this action as a precaution because of reports of a rare, but serious, eye infection, Acanthamoeba keratitis caused by a parasite. The link between the solution and the infection was identified as a result of an investigation by the Centers for Disease Control and Prevention (CDC).
Consumers who wear soft contact lenses should stop using the solution, discard all partially-used or unopened bottles and replace their lenses and storage container."We believe the company acted responsibly in taking this voluntary action and support their decision to be proactive in the interest of public health," said Daniel Schultz, M.D., director of FDA's Center for Devices and Radiological Health. "FDA and CDC are working closely with the company to collect additional information and we will continue to alert consumers and advise them as more information becomes available."
Acanthamoeba keratitis may lead to vision loss with some patients requiring a corneal transplant. The infection primarily affects otherwise healthy people who wear contact lenses.Consumers should ask their doctor about choosing an appropriate alternative cleaning/disinfecting product and seek immediate treatment if they have symptoms of eye infection as early diagnosis is important for effective treatment. The symptoms of Acanthamoeba keratitis can be very similar to those of other more common eye infections and may include eye pain or redness, blurred vision, light sensitivity, sensation of something in the eye or excessive tearing but Acanthamoeba is more difficult to treat.
It is estimated that Acanthamoeba keratitis infections occur in approximately 2 out of every 1 million contact lens users in the United States each year. However, in a multi-state investigation to evaluate a recent increase in Acanthamoeba keratitis cases, CDC determined that the risk of developing AK was at least seven times greater for those consumers who used Complete MoisturePlus solution versus those who did not. Additional information regarding the CDC results is available at the CDC website http://www.cdc.gov/mmwr/preview/mmwrhtml/mm56d526a1.htm.
"The ongoing CDC investigation is a collaborative effort," said Michael Beach, M.D., a Division of Parasitic Diseases team leader with CDC. "We are working with FDA, state, territory, university, and clinical partners in an effort to further understand whether usage or contamination of this solution led to these Acanthamoeba infections."
- All contact lens users should closely adhere to the following measures to help prevent eye infections
- Remove contact lenses before any activity involving contact with water, including showering, using a hot tub, or swimming.
- Wash hands with soap and water and dry them before handling contact lenses.
- Clean contact lenses according to manufacturer guidelines and instructions from an eye care professional.
- Use fresh cleaning or disinfecting solution each time lenses are cleaned and stored. Never reuse or top off old solution.
- Never use saline solution and rewetting drops to disinfect lenses. Neither solution is an effective or approved disinfectant.
- Schedule regular eye exams with your eye care professional.
- Wear and replace contact lenses according to the schedule prescribed by your eye care professional.
- Store lenses in a proper storage case.
- Storage cases should be irrigated with sterile contact lens solution (never use tap water) and left open to dry after each use.
- Replace storage cases at least once every three months.
Legal Help for Keratitis Contact Lens Solution Victims
If you or a loved one has used contact solution and have been recently diagnosed with keratitis, then you may have a right to file individual legal action against the product manufacturer. Due to the nature of this serious infection, consumers diagnosed with keratitis are urged to contact an attorney immediately after they have been informed of their diagnosis. Many important legal issues need to be addressed after a keratitis diagnosis that can possibly affect the outcome of civil litigation. The laws and theories of liability in each state are varied and can limit the amount of time a consumer has to file a lawsuit (statute of limitations). If one waits too long to file a lawsuit, then they may be barred or prevented from bringing such claim, lawsuit or remedy for their injuries and damages.
If you or a loved one has developed keratitis, call us for a free confidential consultation. We understand the complications of serious eye infections like keratitis and are here to help answer your questions. Call or submit our Complete Moisture PlusKeritits Lawsuit form for a free case evaluation. No fees or expenses charged, unless we make a recovery for you: 1-800-883-9858.
Monday, July 30, 2007
First Alert® Smoke Alarm & Smoke /CO Alarms Recalled
First Alert Smoke Alarm Recall
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs
Washington, DC 20207
FOR IMMEDIATE RELEASE
May 2, 2006 Release #06-151
Firm’s Recall Hotline: (800) 323-9005 CPSC Recall Hotline: (800) 638-2772CPSC Media Contact: (301) 504-7908
First Alert® Smoke Alarms and Combination Smoke/CO Alarms Recalled for Rapidly Draining Battery PowerWASHINGTON, D.C. - The U.S. Consumer Product Safety Commission, in cooperation with the firm named below, today announced a voluntary recall of the following consumer product. Consumers should stop using recalled products immediately unless otherwise instructed.
Name of Product: First Alert® ONELINK™ Battery-Powered Smoke and Combination Smoke/Carbon Monoxide (CO) Alarms
Units: About 145,890 (About 52,400 were sold to consumers)
Manufacturer: BRK Brands Inc., a subsidiary of First Alert Inc., of Aurora, Ill.
Fire Hazard: These fire alarms can drain the power from batteries rapidly, causing premature low battery power. Consumers will be alerted to the low battery power and the need to replace the battery by a chirping of the unit. If the batteries on the smoke/CO alarm are not replaced before the battery power terminates, the alarm will not detect smoke in the event of a possible fire and the presence of carbon monoxide.
First Alert Incidents/Injuries: CPSC and First Alert Inc./BRK Brands Inc. have received about 329 reports of premature low battery power in these alarms. There have been no reports of injuries, incidents or alarms failing to detect smoke or carbon monoxide.
First Alert Recall Description: The recall involves ONELINK™ battery-powered smoke and combination smoke/CO alarms. “First Alert” and “ONELINK™” are printed on the front of the alarm. The model number and date code are printed on the back of the alarm. Model number SA500 or SCO500 with a date code prior to March 3, 2006 are included in this recall.
First Alert Alarms sold at: Department, home and hardware stores nationwide from June 2005 through March 2006 for between $45 and $75.
First Alert Smoke Alarm & Smoke / CO Alarms Manufactured In: Mexico
Remedy for recall First Alert Smoke Alarm: Consumers should contact First Alert Inc./BRK Brands Inc. immediately to receive a replacement alarm. Until a new alarm is received, consumers should test the batteries in the alarm weekly by pressing the “test” button. If the alarm signals a low battery alert, consumers should immediately replace the batteries. Consumers should not remove their alarms until they have received a replacement alarm.
First Alert Smoke Alarm Consumer Contact: For more information, contact First Alert Inc./BRK Brands Inc. at (800) 323-9005 between 8:30 a.m. and 6 p.m. ET Monday through Friday or visit the firm's web site at www.firstalert.com -->
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs
Washington, DC 20207
FOR IMMEDIATE RELEASE
May 2, 2006 Release #06-151
Firm’s Recall Hotline: (800) 323-9005 CPSC Recall Hotline: (800) 638-2772CPSC Media Contact: (301) 504-7908
First Alert® Smoke Alarms and Combination Smoke/CO Alarms Recalled for Rapidly Draining Battery PowerWASHINGTON, D.C. - The U.S. Consumer Product Safety Commission, in cooperation with the firm named below, today announced a voluntary recall of the following consumer product. Consumers should stop using recalled products immediately unless otherwise instructed.
Name of Product: First Alert® ONELINK™ Battery-Powered Smoke and Combination Smoke/Carbon Monoxide (CO) Alarms
Units: About 145,890 (About 52,400 were sold to consumers)
Manufacturer: BRK Brands Inc., a subsidiary of First Alert Inc., of Aurora, Ill.
Fire Hazard: These fire alarms can drain the power from batteries rapidly, causing premature low battery power. Consumers will be alerted to the low battery power and the need to replace the battery by a chirping of the unit. If the batteries on the smoke/CO alarm are not replaced before the battery power terminates, the alarm will not detect smoke in the event of a possible fire and the presence of carbon monoxide.
First Alert Incidents/Injuries: CPSC and First Alert Inc./BRK Brands Inc. have received about 329 reports of premature low battery power in these alarms. There have been no reports of injuries, incidents or alarms failing to detect smoke or carbon monoxide.
First Alert Recall Description: The recall involves ONELINK™ battery-powered smoke and combination smoke/CO alarms. “First Alert” and “ONELINK™” are printed on the front of the alarm. The model number and date code are printed on the back of the alarm. Model number SA500 or SCO500 with a date code prior to March 3, 2006 are included in this recall.
First Alert Alarms sold at: Department, home and hardware stores nationwide from June 2005 through March 2006 for between $45 and $75.
First Alert Smoke Alarm & Smoke / CO Alarms Manufactured In: Mexico
Remedy for recall First Alert Smoke Alarm: Consumers should contact First Alert Inc./BRK Brands Inc. immediately to receive a replacement alarm. Until a new alarm is received, consumers should test the batteries in the alarm weekly by pressing the “test” button. If the alarm signals a low battery alert, consumers should immediately replace the batteries. Consumers should not remove their alarms until they have received a replacement alarm.
First Alert Smoke Alarm Consumer Contact: For more information, contact First Alert Inc./BRK Brands Inc. at (800) 323-9005 between 8:30 a.m. and 6 p.m. ET Monday through Friday or visit the firm's web site at www.firstalert.com -->
Amusepark Park Ride Injuries Warning
Girl Ejected on Carnival Ride Critically Injured
NEWS from CPSC
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs
Washington, DC 20207
FOR IMMEDIATE RELEASEJune 9, 2004 Release # 04-156
Wisdom/Gravitron Hotline: (970) 522-7515 CPSC Consumer Hotline: (800) 638-2772 CPSC Media Contact: (301) 504-7908
CPSC, Wisdom Industries Ltd. Announce Revised Safety Inspection Program for Gravitron Mobile Amusement Rides
WASHINGTON, D.C. – The U.S. Consumer Product Safety Commission (CPSC) and Wisdom Industries Ltd., of Sterling, Colo., are announcing a revised safety inspection program for all types of Gravitron amusement rides. The Gravitron amusement ride is a whirling cylinder which uses centrifugal force to hold riders to their seats as the seats rise, giving the illusion that the floor is dropping out. The ride is also called the Starship, Old Blue, and Trip to Mars. There are approximately 190 such rides in the U.S. and Canada.On April 2, 2004, at the Miami-Dade County Fair and Exposition in Florida, a wall panel of the Gravitron ride gave way, ejecting three riders. Seven people were injured, including two bystanders who were hit by debris. Injuries included broken bones, concussions, and bruises. A 16-year-old girl ejected from the ride was critically injured. CPSC’s investigation of this incident and its work with the ride manufacturer, Wisdom Industries Ltd., resulted in a revised safety inspection program to prevent future incidents.
In brief, some of the elements of the inspection program include:
- Inspect welds and steel components for cracks or breaks.
- Inspect platform hinges for cracks or wear.
- Inspect platform hinge bolts for wear.
- Check tire air pressure.
- Measure wing sag to make sure it is level with main table.
- Inspect the underwing alignment bolts for bending and wear.
- Inspect condition of fiberglass at lower end of the panel for wear.
These new safety guidelines have been sent to all owners of Gravitron rides, state inspectors and amusement ride insurers to help improve maintenance of the rides.CPSC and Wisdom Industries announced a modification program to improve the safety of the Gravitron rides in 1992.
That program included the installation of corner pin reinforcement plates, which were in place on the ride involved in the recent incident. The revised safety inspection program should be performed in addition to the previous modification program. Wisdom Industries Ltd. can be reached at (970) 522-7515 or at their Web site: www.wisdomrides.com
MRI Nephrogenic Systemic Fibrosis Lawsuits
MRI Nephrogenic Systemic Fibrosis Lawsuits
FDA reports that a widely used MRI contrast agent is causing Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy (NFD) The Willis Law Firm of Houston, Texas (1-800-883-9858) is currently representing a number of clients with serious complications from gadolinium including several with Nephrogenic Systemic Fibrosis (NSF). The MRI contrast agents, or dyes, that contain gadolinium and were used in patients who suffer from kidney failure and a disease has been linked to causing known as Nephrogenic Systemic Fibrosis (NSF), also called Nephrogenic Fibrosing Dermopathy (NFD). There has not been a Gadolinium recall issed to date.
MRI - Nephrogenic Systemic Fibrosis Links:
Nephrogenic Fibrosing Dermopathy (NFD)
Nephrogenic Fibrosing Dermopathy (NFD) Symptoms
Nephrogenic Fibrosing Dermopathy (NFD) MRI Gadolinium
FDA Requests Boxed Gadolinium Warning
The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI). The requested warning would state that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF). In addition, it would state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity.
"FDA has been carefully monitoring potential safety signals related to these contrast agents after receiving reports about the risk of this potentially life-threatening disease," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "This latest action demonstrates FDA's continuing vigilance about ensuring the safety of drug products once they enter the marketplace." NSF Paitent - Thickening of Skin & Joint ProblemsPatients with NSF develop thickening of the skin and connective tissues that inhibits their ability to move and may result in broken bones. Other organs are at risk of thickening as well. The cause of NSF is not known and there is no consistently effective treatment of this condition.FDA first notified health care professionals and the public about the gadolinium-related risks for NSF in June 2006 . Information on the risks was updated in December.Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents. The reports have not always identified a specific agent. Omniscan was the most commonly reported agent, when a specific agent was identified, followed by Magnevist and OptiMARK.
NSF also has developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports incompletely describe exposure to gadolinium-based contrast agents, it is not possible to know if the extent of risks for developing NSF is the same for all agents. Patients should be screened for kidney problems prior to receiving one of these imaging agents. The recommended dose should not be exceeded and enough time should elapse to ensure that a dose has been eliminated from the body before the agent is used again. There have been no reports of NSF among patients with normal kidney function or those with mild-to-moderate kidney insufficiency.
Bayer Schering Pharma, Berlin, Germany, manufactures Magnevist; GE Healthcare, Chalfont St. Giles, U.K., is the maker of Omniscan; OptiMARK is manufactured by Mallinckrodt, Inc., Hazelwood, Mo.; and ProHance and Multihance are made by Bracco Diagnostics Inc., Princeton,
N.J
Gadolinium Nephrogenic Systemic Fibrosis Lawsuit - Free Case Evaluation
If you or a loved one had a MRI or a MRA, and a contrast dye or agent was used to enhance the MRI image, and you or a loved developed NFS/NFD, kidney failure or renal failure, then you may be eligible to collect money damages for your injuries and damages.
Please fill out our Free Case Evaluation Form to better help us assist you, or call us Toll Free at 1-800-883-9858.
FDA reports that a widely used MRI contrast agent is causing Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy (NFD) The Willis Law Firm of Houston, Texas (1-800-883-9858) is currently representing a number of clients with serious complications from gadolinium including several with Nephrogenic Systemic Fibrosis (NSF). The MRI contrast agents, or dyes, that contain gadolinium and were used in patients who suffer from kidney failure and a disease has been linked to causing known as Nephrogenic Systemic Fibrosis (NSF), also called Nephrogenic Fibrosing Dermopathy (NFD). There has not been a Gadolinium recall issed to date.
MRI - Nephrogenic Systemic Fibrosis Links:
Nephrogenic Systemic Fibrosis (NSF)
Nephrogenic Systemic Fibrosis (NSF) Lawsuit
Nephrogenic Systemic Fibrosis (NSF) Symptoms
Nephrogenic Fibrosing Dermopathy (NFD)
Nephrogenic Fibrosing Dermopathy (NFD) Symptoms
Nephrogenic Fibrosing Dermopathy (NFD) MRI Gadolinium
FDA Requests Boxed Gadolinium Warning
The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI). The requested warning would state that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF). In addition, it would state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity.
"FDA has been carefully monitoring potential safety signals related to these contrast agents after receiving reports about the risk of this potentially life-threatening disease," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "This latest action demonstrates FDA's continuing vigilance about ensuring the safety of drug products once they enter the marketplace." NSF Paitent - Thickening of Skin & Joint ProblemsPatients with NSF develop thickening of the skin and connective tissues that inhibits their ability to move and may result in broken bones. Other organs are at risk of thickening as well. The cause of NSF is not known and there is no consistently effective treatment of this condition.FDA first notified health care professionals and the public about the gadolinium-related risks for NSF in June 2006 . Information on the risks was updated in December.Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents. The reports have not always identified a specific agent. Omniscan was the most commonly reported agent, when a specific agent was identified, followed by Magnevist and OptiMARK.
NSF also has developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports incompletely describe exposure to gadolinium-based contrast agents, it is not possible to know if the extent of risks for developing NSF is the same for all agents. Patients should be screened for kidney problems prior to receiving one of these imaging agents. The recommended dose should not be exceeded and enough time should elapse to ensure that a dose has been eliminated from the body before the agent is used again. There have been no reports of NSF among patients with normal kidney function or those with mild-to-moderate kidney insufficiency.
Bayer Schering Pharma, Berlin, Germany, manufactures Magnevist; GE Healthcare, Chalfont St. Giles, U.K., is the maker of Omniscan; OptiMARK is manufactured by Mallinckrodt, Inc., Hazelwood, Mo.; and ProHance and Multihance are made by Bracco Diagnostics Inc., Princeton,
N.J
Gadolinium Nephrogenic Systemic Fibrosis Lawsuit - Free Case Evaluation
If you or a loved one had a MRI or a MRA, and a contrast dye or agent was used to enhance the MRI image, and you or a loved developed NFS/NFD, kidney failure or renal failure, then you may be eligible to collect money damages for your injuries and damages.
Please fill out our Free Case Evaluation Form to better help us assist you, or call us Toll Free at 1-800-883-9858.
Subscribe to:
Posts (Atom)
